HC Wainwright Reduces Earnings Estimates for Ekso Bionics

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Analysts at HC Wainwright cut their FY2026 EPS estimates for Ekso Bionics in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn $0.00 per share for the year, down from their prior estimate of $0.02. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Ekso Bionics’ FY2027 earnings at $0.12 EPS and FY2029 earnings at $0.46 EPS.

Several other research firms also recently commented on EKSO. StockNews.com initiated coverage on shares of Ekso Bionics in a research note on Monday. They issued a “hold” rating on the stock. Lake Street Capital decreased their price objective on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a research report on Tuesday.

Ekso Bionics Stock Performance

NASDAQ EKSO opened at $0.40 on Wednesday. The stock has a market capitalization of $8.86 million, a PE ratio of -0.62 and a beta of 1.46. The business has a 50 day simple moving average of $0.61 and a two-hundred day simple moving average of $0.82. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. Ekso Bionics has a 1-year low of $0.37 and a 1-year high of $1.64.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). The company had revenue of $5.09 million during the quarter, compared to the consensus estimate of $5.05 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.